StockWatch
·
 Medicinal Chemicals and Botanical Products
Quarterly ResultJul 28, 2026, 06:58 AM

SNDL Q2 Revenue $235.8M, Operating Loss $(7.8)M; Parallel Restructuring Completed

AI Summary

SNDL Inc. reported Q2 2026 financial results with net revenue decreasing 3.7% to $235.8 million and an operating loss of $(7.8) million, driven by market headwinds and production ramp-up costs. Despite negative cash flow, free cash flow improved year-over-year, and the company maintained a debt-free balance sheet with strong liquidity. A significant strategic milestone was the completion of the Parallel restructuring, which is expected to add US$150 million in annualized revenue and position SNDL as a leading vertically integrated cannabis operator in North America.

Key Highlights

  • Net revenue for Q2 2026 was $235.8 million, a -3.7% decrease year-over-year.
  • Gross profit declined -16.6% to $56.3 million, with gross margin at 23.9%.
  • Operating loss was $(7.8) million, a reduction of $(12.8) million compared to prior year.
  • Free cash flow was negative $(6.7) million, an improvement of $1.2 million year-over-year.
  • SNDL repurchased 11.7 million common shares for $23.5 million in Q2 2026.
  • Unrestricted cash stood at $183.2 million with no debt as of June 30, 2026.
  • Restructuring of Parallel completed, expected to add US$150 million annualized revenue.
  • Cannabis Retail net revenue was $83.2 million (-1.4%) and Liquor Retail net revenue was $134.7 million (-5.1%).